Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients
Introduction Asian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary granulocyte colony‐stimulating factor (GCSF) for preventing FN in Chinese patients with metastatic hormone‐sensitive PC (mHSPC) and castration‐resistant P...
Saved in:
Published in | Asia-Pacific journal of clinical oncology Vol. 17; no. S3; pp. 39 - 47 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
Wiley Subscription Services, Inc
01.04.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Introduction
Asian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary granulocyte colony‐stimulating factor (GCSF) for preventing FN in Chinese patients with metastatic hormone‐sensitive PC (mHSPC) and castration‐resistant PC (mCRPC).
Patients and Methods
Data from two cohorts of 377 Chinese patients with mHSPC (100; 26.5%) and mCRPC (277; 73.5%) treated with docetaxel at six public oncology centres were analysed with multivariate regression. Primary GCSF prophylaxis was defined as administration within 5 days of starting docetaxel. The primary outcome was FN within 21 days of the first docetaxel cycle (1st FN).
Results
Primary GCSF was given to 71 (18.8%) patients. FN occurred in 61 patients (16.2%) including 37 (9.8%) during the first cycle. Among patients who developed 1st cycle FN (n = 37) or not (n = 340), 2 and 69 received primary GCSF (5.4 vs. 20.3%, P = .03). Primary GCSF was associated with an overall reduced risk of 1st cycle FN (odds ratio [OR] = 0.22; 95% confidence interval [CI]: 0.05‐0.96, P = .04), and similar trends were observed in the mHSPC (OR = 0.36, P = .35) and mCRPC (OR = 0.16, P = .08) subgroups. Poor Eastern Cooperative Oncology Group performance status (>1) was associated with an increased risk of 1st FN (OR = 3.90; 95% CI: 1.66‐9.13, P = .002).
Conclusions
To alleviate the risk of docetaxel‐related FN, primary GCSF prophylaxis is suggested for Asian mCRPC and mHSPC patients, particularly those with poor performance status. |
---|---|
AbstractList | Introduction
Asian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary granulocyte colony‐stimulating factor (GCSF) for preventing FN in Chinese patients with metastatic hormone‐sensitive PC (mHSPC) and castration‐resistant PC (mCRPC).
Patients and Methods
Data from two cohorts of 377 Chinese patients with mHSPC (100; 26.5%) and mCRPC (277; 73.5%) treated with docetaxel at six public oncology centres were analysed with multivariate regression. Primary GCSF prophylaxis was defined as administration within 5 days of starting docetaxel. The primary outcome was FN within 21 days of the first docetaxel cycle (1st FN).
Results
Primary GCSF was given to 71 (18.8%) patients. FN occurred in 61 patients (16.2%) including 37 (9.8%) during the first cycle. Among patients who developed 1st cycle FN (n = 37) or not (n = 340), 2 and 69 received primary GCSF (5.4 vs. 20.3%, P = .03). Primary GCSF was associated with an overall reduced risk of 1st cycle FN (odds ratio [OR] = 0.22; 95% confidence interval [CI]: 0.05‐0.96, P = .04), and similar trends were observed in the mHSPC (OR = 0.36, P = .35) and mCRPC (OR = 0.16, P = .08) subgroups. Poor Eastern Cooperative Oncology Group performance status (>1) was associated with an increased risk of 1st FN (OR = 3.90; 95% CI: 1.66‐9.13, P = .002).
Conclusions
To alleviate the risk of docetaxel‐related FN, primary GCSF prophylaxis is suggested for Asian mCRPC and mHSPC patients, particularly those with poor performance status. Asian prostate cancer (PC) patients are particularly susceptible to docetaxel-related febrile neutropenia (FN). We evaluated primary granulocyte colony-stimulating factor (GCSF) for preventing FN in Chinese patients with metastatic hormone-sensitive PC (mHSPC) and castration-resistant PC (mCRPC). Data from two cohorts of 377 Chinese patients with mHSPC (100; 26.5%) and mCRPC (277; 73.5%) treated with docetaxel at six public oncology centres were analysed with multivariate regression. Primary GCSF prophylaxis was defined as administration within 5 days of starting docetaxel. The primary outcome was FN within 21 days of the first docetaxel cycle (1st FN). Primary GCSF was given to 71 (18.8%) patients. FN occurred in 61 patients (16.2%) including 37 (9.8%) during the first cycle. Among patients who developed 1st cycle FN (n = 37) or not (n = 340), 2 and 69 received primary GCSF (5.4 vs. 20.3%, P = .03). Primary GCSF was associated with an overall reduced risk of 1st cycle FN (odds ratio [OR] = 0.22; 95% confidence interval [CI]: 0.05-0.96, P = .04), and similar trends were observed in the mHSPC (OR = 0.36, P = .35) and mCRPC (OR = 0.16, P = .08) subgroups. Poor Eastern Cooperative Oncology Group performance status (>1) was associated with an increased risk of 1st FN (OR = 3.90; 95% CI: 1.66-9.13, P = .002). To alleviate the risk of docetaxel-related FN, primary GCSF prophylaxis is suggested for Asian mCRPC and mHSPC patients, particularly those with poor performance status. Abstract Introduction Asian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary granulocyte colony‐stimulating factor (GCSF) for preventing FN in Chinese patients with metastatic hormone‐sensitive PC (mHSPC) and castration‐resistant PC (mCRPC). Patients and Methods Data from two cohorts of 377 Chinese patients with mHSPC (100; 26.5%) and mCRPC (277; 73.5%) treated with docetaxel at six public oncology centres were analysed with multivariate regression. Primary GCSF prophylaxis was defined as administration within 5 days of starting docetaxel. The primary outcome was FN within 21 days of the first docetaxel cycle (1st FN). Results Primary GCSF was given to 71 (18.8%) patients. FN occurred in 61 patients (16.2%) including 37 (9.8%) during the first cycle. Among patients who developed 1st cycle FN (n = 37) or not (n = 340), 2 and 69 received primary GCSF (5.4 vs. 20.3%, P = .03). Primary GCSF was associated with an overall reduced risk of 1st cycle FN (odds ratio [OR] = 0.22; 95% confidence interval [CI]: 0.05‐0.96, P = .04), and similar trends were observed in the mHSPC (OR = 0.36, P = .35) and mCRPC (OR = 0.16, P = .08) subgroups. Poor Eastern Cooperative Oncology Group performance status (>1) was associated with an increased risk of 1st FN (OR = 3.90; 95% CI: 1.66‐9.13, P = .002). Conclusions To alleviate the risk of docetaxel‐related FN, primary GCSF prophylaxis is suggested for Asian mCRPC and mHSPC patients, particularly those with poor performance status. IntroductionAsian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary granulocyte colony‐stimulating factor (GCSF) for preventing FN in Chinese patients with metastatic hormone‐sensitive PC (mHSPC) and castration‐resistant PC (mCRPC).Patients and MethodsData from two cohorts of 377 Chinese patients with mHSPC (100; 26.5%) and mCRPC (277; 73.5%) treated with docetaxel at six public oncology centres were analysed with multivariate regression. Primary GCSF prophylaxis was defined as administration within 5 days of starting docetaxel. The primary outcome was FN within 21 days of the first docetaxel cycle (1st FN).ResultsPrimary GCSF was given to 71 (18.8%) patients. FN occurred in 61 patients (16.2%) including 37 (9.8%) during the first cycle. Among patients who developed 1st cycle FN (n = 37) or not (n = 340), 2 and 69 received primary GCSF (5.4 vs. 20.3%, P = .03). Primary GCSF was associated with an overall reduced risk of 1st cycle FN (odds ratio [OR] = 0.22; 95% confidence interval [CI]: 0.05‐0.96, P = .04), and similar trends were observed in the mHSPC (OR = 0.36, P = .35) and mCRPC (OR = 0.16, P = .08) subgroups. Poor Eastern Cooperative Oncology Group performance status (>1) was associated with an increased risk of 1st FN (OR = 3.90; 95% CI: 1.66‐9.13, P = .002).ConclusionsTo alleviate the risk of docetaxel‐related FN, primary GCSF prophylaxis is suggested for Asian mCRPC and mHSPC patients, particularly those with poor performance status. |
Author | Chan, Tim‐Wai Lee, Ka Chai Poon, Darren M.C. Siu, Steven Chan, Kuen Johnson, David Ng, Bryan Ng, Joyce |
Author_xml | – sequence: 1 givenname: Darren M.C. surname: Poon fullname: Poon, Darren M.C. email: mc_poon@clo.cuhk.edu.hk organization: Hong Kong Sanatorium & Hospital – sequence: 2 givenname: Kuen surname: Chan fullname: Chan, Kuen organization: Pamela Youde Nethersole Eastern Hospital – sequence: 3 givenname: Tim‐Wai surname: Chan fullname: Chan, Tim‐Wai organization: Queen Elizabeth Hospital – sequence: 4 givenname: Bryan surname: Ng fullname: Ng, Bryan organization: Princess Margaret Hospital – sequence: 5 givenname: Steven surname: Siu fullname: Siu, Steven organization: Queen Mary Hospital – sequence: 6 givenname: Joyce surname: Ng fullname: Ng, Joyce organization: The Chinese University of Hong Kong – sequence: 7 givenname: David surname: Johnson fullname: Johnson, David organization: The Chinese University of Hong Kong – sequence: 8 givenname: Ka Chai surname: Lee fullname: Lee, Ka Chai organization: Tuen Mun Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33860642$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtu2zAQhonCRfNoNz1AQKC7Ak5FUdRjaRhpkyCAs0jXAk0ObRoS6ZBUUu96hN4rt8hJMoqdLMvNEJxv_pnhf0Imzjsg5CvLzhmeH3Kj_Dnjoqo_kGNWFXxaiZJP3u9CHJGTGDdZxpu8YZ_IEed1mZVFfkyebgM8gEvWO-oN1V5Bkn-ge_77T8bolZUJNDWwDLYD6mBIwW_BWUkfbVrTbbC9DDu6CtINnVe7BFT5zrsdCsRk-6GTyboVNVIlH6h1dL62DiLQHhvFhFlF1z70uNJYAi7aZB-ASqepQiDIcTZMBYgWeZewqR8LsZN0CgLdIoIrxM_ko5FdhC-HeEp-_7y4m19Obxa_ruazm6niDa-ngudGMCVYpqHRqi7ySjZLlquMiYoZUwkoJS9rU0IFotANPmumlkXFdWFEzU_Jt70uDnI_QEztxg_BYcs2FyxvihwDUt_3lMJxYwDTHj6rZVk7-taOvrWvviF8dpAclj3od_TNKATYHnhEH3b_kWpn1_PFXvQFoI2v9A |
CitedBy_id | crossref_primary_10_1177_17588359231216582 crossref_primary_10_1016_j_clgc_2023_07_012 crossref_primary_10_3390_cancers14020407 crossref_primary_10_1002_pros_24406 crossref_primary_10_1111_bju_16106 crossref_primary_10_1177_17588359221131525 |
Cites_doi | 10.7314/APJCP.2014.15.8.3443 10.1016/S0140-6736(15)01037-5 10.1002/cam4.344 10.1093/annonc/mdt397 10.1016/j.ygyno.2012.03.015 10.1007/s00520-010-0821-1 10.1056/NEJMoa040720 10.1016/S1470-2045(12)70560-0 10.1007/s12032-016-0793-1 10.1186/s12957-019-1665-x 10.1200/JCO.2006.06.4451 10.1111/bjh.13026 10.1016/j.critrevonc.2013.12.006 10.1007/s00520-018-4224-z 10.1016/j.clgc.2016.05.012 10.1002/cam4.2003 10.1093/jnci/djt198 10.1016/j.eururo.2020.01.012 10.1111/ajco.12874 10.3111/13696998.2013.844160 10.1016/j.prnil.2015.03.002 10.1111/ajco.12840 10.1007/s00520-015-2686-9 10.1056/NEJMoa041318 10.1056/NEJMoa1503747 10.1200/JCO.2011.39.9436 10.1016/j.ejca.2010.10.013 |
ContentType | Journal Article |
Copyright | 2021 John Wiley & Sons Australia, Ltd 2021 John Wiley & Sons Australia, Ltd. |
Copyright_xml | – notice: 2021 John Wiley & Sons Australia, Ltd – notice: 2021 John Wiley & Sons Australia, Ltd. |
CorporateAuthor | Hong Kong Society of Uro-Oncology (HKSUO) Hong Kong Society of Uro‐Oncology (HKSUO) |
CorporateAuthor_xml | – name: Hong Kong Society of Uro-Oncology (HKSUO) – name: Hong Kong Society of Uro‐Oncology (HKSUO) |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO H94 |
DOI | 10.1111/ajco.13578 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitleList | MEDLINE CrossRef Oncogenes and Growth Factors Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1743-7563 |
EndPage | 47 |
ExternalDocumentID | 10_1111_ajco_13578 33860642 AJCO13578 |
Genre | article Multicenter Study Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- .3N .GA 05W 0R~ 10A 1OC 23N 31~ 33P 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFZJQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM EBD EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZ~ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WVDHM WXSBR XG1 ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TO H94 |
ID | FETCH-LOGICAL-c3938-532f51c510de9dc8427a9b12c01571ff75e6a368f6e7e54d9157d1cb473d4f583 |
IEDL.DBID | DR2 |
ISSN | 1743-7555 |
IngestDate | Fri Sep 13 02:32:45 EDT 2024 Fri Aug 23 01:04:26 EDT 2024 Sat Sep 28 08:22:59 EDT 2024 Sat Aug 24 01:04:18 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | S3 |
Keywords | prostate cancer febrile neutropenia granulocyte colony-stimulating factor docetaxel metastasis |
Language | English |
License | 2021 John Wiley & Sons Australia, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3938-532f51c510de9dc8427a9b12c01571ff75e6a368f6e7e54d9157d1cb473d4f583 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajco.13578 |
PMID | 33860642 |
PQID | 2512942251 |
PQPubID | 2045194 |
PageCount | 9 |
ParticipantIDs | proquest_journals_2512942251 crossref_primary_10_1111_ajco_13578 pubmed_primary_33860642 wiley_primary_10_1111_ajco_13578_AJCO13578 |
PublicationCentury | 2000 |
PublicationDate | April 2021 2021-Apr 2021-04-00 20210401 |
PublicationDateYYYYMMDD | 2021-04-01 |
PublicationDate_xml | – month: 04 year: 2021 text: April 2021 |
PublicationDecade | 2020 |
PublicationPlace | Australia |
PublicationPlace_xml | – name: Australia – name: Chichester |
PublicationTitle | Asia-Pacific journal of clinical oncology |
PublicationTitleAlternate | Asia Pac J Clin Oncol |
PublicationYear | 2021 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2019; 8 2014; 90 2015; 3 2013; 24 2013; 105 2019; 17 2016; 387 2020; 77 2012; 125 2011; 19 2018; 26 2012; 30 2016; 33 2015; 23 2004; 351 2013; 14 2014; 3 2017; 15 2006; 24 2019; 46 2015; 373 2014; 15 2014; 17 2011; 47 2018; 14 2014; 167 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_25_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 Koutake Y (e_1_2_8_11_1) 2019; 46 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_10_1 e_1_2_8_12_1 |
References_xml | – volume: 14 start-page: 347 issue: 4 year: 2018 end-page: 352 article-title: Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone‐naive prostate cancer: the first real‐life experience in Asia publication-title: Asia Pac J Clin Oncol – volume: 3 start-page: 1477 issue: 6 year: 2014 end-page: 1484 article-title: G‐CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use publication-title: Cancer Med – volume: 26 start-page: 3691 issue: 11 year: 2018 end-page: 3699 article-title: Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy publication-title: Support Care Cancer – volume: 351 start-page: 1502 issue: 15 year: 2004 end-page: 1512 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer publication-title: N Engl J Med – volume: 24 start-page: 2972 issue: 12 year: 2013 end-page: 2977 article-title: Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials publication-title: Ann Oncol – volume: 3 start-page: 51 issue: 2 year: 2015 end-page: 55 article-title: Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration‐resistant prostate cancer publication-title: Prostate Int – volume: 125 start-page: 625 issue: 3 year: 2012 end-page: 630 article-title: Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer publication-title: Gynecol Oncol – volume: 77 start-page: 508 issue: 4 year: 2020 end-page: 547 article-title: Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019 publication-title: Eur Urol – volume: 387 start-page: 1163 issue: 10024 year: 2016 end-page: 1177 article-title: Addition of docetaxel, zoledronic acid, or both to first‐line long‐term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial publication-title: Lancet – volume: 90 start-page: 190 issue: 3 year: 2014 end-page: 199 article-title: Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review publication-title: Crit Rev Oncol Hematol – volume: 105 start-page: 1072 issue: 15 year: 2013 end-page: 1073 article-title: Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost‐effectiveness analysis publication-title: J Natl Cancer Inst – volume: 14 start-page: e399 issue: 5 year: 2018 end-page: e404 article-title: Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose‐reduced 3‐weekly docetaxel for metastatic castration‐resistant prostate cancer publication-title: Asia Pac J Clin Oncol – volume: 47 start-page: 8 issue: 1 year: 2011 end-page: 32 article-title: 2010 update of EORTC guidelines for the use of granulocyte‐colony stimulating factor to reduce the incidence of chemotherapy‐induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours publication-title: Eur J Cancer – volume: 17 start-page: 32 issue: 1 year: 2014 end-page: 42 article-title: Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non‐Hodgkin's lymphoma: cost‐effectiveness analyses publication-title: J Med Econ – volume: 19 start-page: 333 issue: 3 year: 2011 end-page: 341 article-title: Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer publication-title: Support Care Cancer – volume: 14 start-page: 149 issue: 2 year: 2013 end-page: 158 article-title: Androgen‐deprivation therapy alone or with docetaxel in non‐castrate metastatic prostate cancer (GETUG‐AFU 15): a randomised, open‐label, phase 3 trial publication-title: Lancet Oncol – volume: 24 start-page: 3187 issue: 19 year: 2006 end-page: 3205 article-title: 2006 update of recommendations for the use of white blood cell growth factors: an evidence‐based clinical practice guideline publication-title: J Clin Oncol – volume: 17 start-page: 125 issue: 1 year: 2019 article-title: Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5‐fluorouracil publication-title: World J Surg Oncol – volume: 373 start-page: 737 issue: 8 year: 2015 end-page: 746 article-title: Chemohormonal therapy in metastatic hormone‐sensitive prostate cancer publication-title: N Engl J Med – volume: 351 start-page: 1513 issue: 15 year: 2004 end-page: 1520 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N Engl J Med – volume: 15 start-page: 176 issue: 1 year: 2017 end-page: 181 article-title: Development of a nomogram for predicting severe neutropenia associated with docetaxel‐based chemotherapy in patients with castration‐resistant prostate cancer publication-title: Clin Genitourin Cancer – volume: 33 start-page: 77 issue: 7 year: 2016 article-title: Docetaxel‐related toxicity in metastatic hormone‐sensitive and metastatic castration‐resistant prostate cancer publication-title: Med Oncol – volume: 167 start-page: 699 issue: 5 year: 2014 end-page: 702 article-title: Impact of body mass index on incidence of febrile neutropenia and treatment‐related mortality in United States veterans with diffuse large B‐cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone publication-title: Br J Haematol – volume: 46 start-page: 1721 issue: 11 year: 2019 end-page: 1725 article-title: Efficacy of primary prophylaxis with pegfilgrastim after docetaxel for castration‐resistant prostate cancer publication-title: Gan To Kagaku Ryoho – volume: 8 start-page: 1406 issue: 4 year: 2019 end-page: 1415 article-title: Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: a meta‐analysis and evaluation of a clinical cohort publication-title: Cancer Med – volume: 15 start-page: 3443 issue: 8 year: 2014 end-page: 3446 article-title: Predictive factors for neutropenia after docetaxel‐based systemic chemotherapy in Korean patients with castration‐ resistant prostate cancer publication-title: Asian Pac J Cancer Prev – volume: 30 start-page: 1553 issue: 13 year: 2012 end-page: 1561 article-title: Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline publication-title: J Clin Oncol – volume: 23 start-page: 3131 issue: 11 year: 2015 end-page: 3140 article-title: The impact of primary prophylaxis with granulocyte colony‐stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta‐analysis of randomized controlled trials publication-title: Support Care Cancer – ident: e_1_2_8_10_1 doi: 10.7314/APJCP.2014.15.8.3443 – ident: e_1_2_8_5_1 doi: 10.1016/S0140-6736(15)01037-5 – ident: e_1_2_8_19_1 doi: 10.1002/cam4.344 – ident: e_1_2_8_20_1 doi: 10.1093/annonc/mdt397 – ident: e_1_2_8_23_1 doi: 10.1016/j.ygyno.2012.03.015 – ident: e_1_2_8_21_1 doi: 10.1007/s00520-010-0821-1 – ident: e_1_2_8_2_1 doi: 10.1056/NEJMoa040720 – ident: e_1_2_8_7_1 doi: 10.1016/S1470-2045(12)70560-0 – volume: 46 start-page: 1721 issue: 11 year: 2019 ident: e_1_2_8_11_1 article-title: Efficacy of primary prophylaxis with pegfilgrastim after docetaxel for castration‐resistant prostate cancer publication-title: Gan To Kagaku Ryoho contributor: fullname: Koutake Y – ident: e_1_2_8_18_1 doi: 10.1007/s12032-016-0793-1 – ident: e_1_2_8_12_1 doi: 10.1186/s12957-019-1665-x – ident: e_1_2_8_15_1 doi: 10.1200/JCO.2006.06.4451 – ident: e_1_2_8_27_1 doi: 10.1111/bjh.13026 – ident: e_1_2_8_6_1 doi: 10.1016/j.critrevonc.2013.12.006 – ident: e_1_2_8_22_1 doi: 10.1007/s00520-018-4224-z – ident: e_1_2_8_24_1 doi: 10.1016/j.clgc.2016.05.012 – ident: e_1_2_8_28_1 doi: 10.1002/cam4.2003 – ident: e_1_2_8_29_1 doi: 10.1093/jnci/djt198 – ident: e_1_2_8_17_1 doi: 10.1016/j.eururo.2020.01.012 – ident: e_1_2_8_8_1 doi: 10.1111/ajco.12874 – ident: e_1_2_8_14_1 doi: 10.3111/13696998.2013.844160 – ident: e_1_2_8_9_1 doi: 10.1016/j.prnil.2015.03.002 – ident: e_1_2_8_25_1 doi: 10.1111/ajco.12840 – ident: e_1_2_8_13_1 doi: 10.1007/s00520-015-2686-9 – ident: e_1_2_8_3_1 doi: 10.1056/NEJMoa041318 – ident: e_1_2_8_4_1 doi: 10.1056/NEJMoa1503747 – ident: e_1_2_8_26_1 doi: 10.1200/JCO.2011.39.9436 – ident: e_1_2_8_16_1 doi: 10.1016/j.ejca.2010.10.013 |
SSID | ssj0039291 |
Score | 2.281443 |
Snippet | Introduction
Asian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary granulocyte... Asian prostate cancer (PC) patients are particularly susceptible to docetaxel-related febrile neutropenia (FN). We evaluated primary granulocyte... Abstract Introduction Asian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary... IntroductionAsian prostate cancer (PC) patients are particularly susceptible to docetaxel‐related febrile neutropenia (FN). We evaluated primary granulocyte... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 39 |
SubjectTerms | Adult Aged Aged, 80 and over Castration China Cohort Studies Colonies Disease prevention docetaxel Docetaxel - adverse effects febrile neutropenia Febrile Neutropenia - chemically induced Granulocyte Colony-Stimulating Factor - therapeutic use granulocyte colony‐stimulating factor Granulocytes Humans Leukocytes (granulocytic) Male Metastases Metastasis Middle Aged Neutropenia Oncology Prophylaxis Prostate cancer Prostatic Neoplasms, Castration-Resistant - complications Prostatic Neoplasms, Castration-Resistant - drug therapy Retrospective Studies |
Title | Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fajco.13578 https://www.ncbi.nlm.nih.gov/pubmed/33860642 https://www.proquest.com/docview/2512942251/abstract/ |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dahQxFA6lF8Ubtf6uVgnolTDFTJLJDPSmFEspVEEs9EaGTHJSV21GdmbBetVH8L18C5_EczIz21ZB0LtlZyeZ3fP3new532HsuWhUsMo0GYYqnSlAWZTGYaoCoG0hVf7SUaPw0evi4FgdnuiTNbYz9cIM_BCrAzeyjOSvycBt010xcvvRtTS1wVCnLzHpESJ6u-KOorgvhm5ImRmt9chNSmU8l7dej0Z_QMzriDWFnP1b7P30sEOlyaftZd9su2-_8Tj-77e5zW6OWJTvDsqzydYg3mEbR-O_7XfZj4nfqY28DdxjqOvtV_j88-K7HaUKngfMqnFLHmHZ08l-nFtOp7v8y0BkwU8xHC4xZp73wIkjO57jAuhZztLksHjKh5k_fB45TfOGDvgZbkStTnPHPyCobiPQLVRrT96Z2-i5sxPjL15aQEc4OPa4aZt6pPA6qvOCj7yx3T12vP_q3d5BNg5_yJys0AlrmQctHLoMD5V3pcqNrRqRO8QvRoRgNBRWFmUowIBWvsK3vXCNMtKroEt5n61HfLyHjBdaFsFCJUKJ6FCAlV5XNOs9-Mpra2bs2aQE9fjT1FNuRHKpk1xmbGvSj3q0864mdFgp9Ilixh4MOrNaApP_gtK7GXuRJP-Xtevdw7036dWjf_nwY3YjpxKbVEi0xdb7xRKeIEbqm6fJFn4BRhQXLA |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELagSMCFf8pCAUtwQkrVJHacHKuKaindIqFW6i1y7HFZaB20yUqUE4_Ae_EWPAkzjrNQkJDgttps7OzO3zfemW8Ye542wmmhmgRDlUwEoCxKZTBVAZC6yEW2ZahReHZQTI_E3rE8jrU51Asz8EOsDtzIMoK_JgOnA-lfrFy_Ny2NbVDlZXYF7V2GjOrtij2KIn869EPmiZJSRnZSKuT5ee_FePQHyLyIWUPQ2b05TFbtAlch1Zp82Fz2zab5_BuT439_n1vsRoSjfHvQn9vsEvg77Oos_uF-l30bKZ5az1vHLUa7Xn-C0-9fvuooWLDcYWKNe3IPy54O9_1cczrg5R8HLgt-ghFxiWHzvAdONNn-HBdA53IWhof5Ez6M_eFzz2mgN3TAz3Aj6naaG_4OcXXrgW6hcnty0Fx7y40eSX_x0gI6gsK-x03b0CaF11GjFzxSx3b32NHuy8OdaRLnPyQmr9APyzxzMjXoNSxU1pQiU7pq0swghFGpc0pCofOidAUokMJW-LZNTSNUboWTZX6frXl8vAeMFzIvnIYqdSUCxBR0bmVF496drazUasKejVpQx5-mHtMjkksd5DJhG6OC1NHUu5oAYiXQLaYTtj4ozWoJzP8LyvAm7EUQ_V_Wrrf3dt6EVw__5cNP2bXp4Wy_3n918PoRu55RxU2oK9pga_1iCY8RMvXNk2AYPwCUWhtO |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEB2VIlW8cL8ECqwET0iusHfXa0u8VC1RKbQgRKW-IGu9O1sCdFMljkR54hP4L_6CL2HGl0BBQoK3KI53ncztzGbmDMDDtFbBKlMnFKp0opBkURhHqQqitrlU2WPHjcJ7-_nOgdo91Icr8GTohen4IZYHbmwZrb9mAz_x4Rcjt-_dlKc2mOIcnFe5zFint18vyaM48KddO6RMjNa6JyflOp6f954NR39gzLOQtY0540vwdnjartTkw8aiqTfc59-IHP_361yGiz0YFZud9lyBFYxXYW2v_7v9GnwbCJ6mUUyD8BTrGvsJP37_8tX2YkUvAqXVtKWIuGj4aD9OrODjXXHSMVmII4qHCwqapw0KJsmOp7QAuZbjdnRYPBLd0B8xiYLHeeMcxTFtxL1OEyfeEaqeRuRbuNie3bOw0QtnB8pfujTDOQPh2NCm07ZJiq6TPs9ETxw7vw4H46dvtnaSfvpD4mRJXljLLOjUkc_wWHpXqMzYsk4zRwDGpCEYjbmVeRFyNKiVL-ltn7paGelV0IW8AauRHu8WiFzLPFgs01AQPEzRSq9LHvYefOm1NSN4MChB1f801ZAcsVyqVi4jWB_0o-oNfV4xPCwVOcV0BDc7nVkuQdl_zvndCB61kv_L2tXm7tbL9tXtf_nwfVh7tT2uXjzbf34HLmRcbtMWFa3DajNb4F3CS019rzWLH06gGf0 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevention+of+docetaxel%E2%80%90associated+febrile+neutropenia+with+primary+granulocyte+colony%E2%80%90stimulating+factor+in+Chinese+metastatic+hormone%E2%80%90sensitive+and+castration%E2%80%90resistant+prostate+cancer+patients&rft.jtitle=Asia-Pacific+journal+of+clinical+oncology&rft.au=Poon%2C+Darren+M.C.&rft.au=Chan%2C+Kuen&rft.au=Chan%2C+Tim%E2%80%90Wai&rft.au=Ng%2C+Bryan&rft.date=2021-04-01&rft.issn=1743-7555&rft.eissn=1743-7563&rft.volume=17&rft.spage=39&rft.epage=47&rft_id=info:doi/10.1111%2Fajco.13578&rft.externalDBID=10.1111%252Fajco.13578&rft.externalDocID=AJCO13578 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-7555&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-7555&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-7555&client=summon |